Genome-wide transcriptional effects in RA (rheumatoid arthritis) patients, undergoing treatment with several disease-modifying drugs (DMARDs).
Purpose: What are the genetic differences in RA patients, before and after DMARD treatment?
Does DMARD treatment affect expression levels?
What are the differences in genetic expression levels in RA patients, compared to healthy control samples?
What are the differences in genetic expression levels in RA patients, before and after DMARD treatment?
What types of biological molecules are the common upstream regulators?
How does the treatment change the influence of the upstream regulators?
Which modules are the target molecules involved in?